Christopher Brittain
Global Vice President, Head of Ophthalmology Product Development, Genentech
Christopher Brittain is listed as Global Vice President, Head of Ophthalmology Product Development, Genentech. Christopher is scheduled to speak at American Society of Retina Specialists Annual Meeting 2027 on 28 July 2027.
Compiled from published conference agendas; not yet confirmed by Christopher. Is this you? Claim this profile.
About
Christopher Brittain, MD, is senior vice president and global head of ophthalmology product development at Genentech/Roche, where he is responsible for development of medicines for ophthalmic diseases. He has overseen global approvals for multiple indications and, more recently, for patients with thyroid eye disease. Prior to moving to the United States in 2016, Dr. Brittain joined Roche in Basel, Switzerland in 2014; there, he led the medical affairs team working on lampalizumab, which was investigated for geographic atrophy.
Upcoming
American Society of Retina Specialists Annual Meeting 2027 28 July 2027 – 31 July 2027
- Keynote Lecture by Christopher Brittain, MD Keynote · 28 July 2027
Others from Genentech
- Kimberley Homan Senior Director, Complex in Vitro Systems Group 2 sessions
- Meena Narayanan Senior Scientist - Process Analytics 2 sessions
- Vladimir Bantseev Distinguished Scientist/Toxicologist and Tox Therapeutic Area Lead for Ophthalmology 2 sessions
- Catrin Hasselgren Executive Director, Predictive Toxicology 1 session
- Luca Finelli VP, Global Head of Data Science, Analytics and Imaging 1 session
- Thomas P. Garner Principal Scientist (Biophysics) 1 session